Mirtazapine: Clinical advantages in the treatment of depression

Journal of Clinical Psychopharmacology

Volumn 17, Issue 2 SUPPL. 1, 1997, Pages

  Burrows, Graham D ^a   Kremer, Charlotte M E ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MIRTAZAPINE;

CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; WEIGHT GAIN;

ADULT; AGED; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS; CLOMIPRAMINE; DEPRESSIVE DISORDER; EATING DISORDERS; HUMANS; MIANSERIN; SLEEP STAGES; WEIGHT GAIN;

EID: 0030897634     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. 2-antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol 1994; 253:R5-6.
2. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995;10:19-23.
3. Ruigt GSF, Kemp B, Groenhout CM, Kamphuisen HAC. Effect of the antidepressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990;38:551-4.
4. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol 1995;10[suppl 4]:25-35.
5. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995;10[suppl 4]:37-45.
6. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995; 56:519-25.
7. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995;34: 165-71.
8. Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depression. Psychopharmacol Bull 1990;26:191-6.
9. Khan MC. A randomised, double-blind, placebo-controlled, 5-weeks' study of Org 3770 (mirtazapine) in major depression. Hum Psychopharmacol 1995;10[suppl 2]:S119-24.
10. Vartiainen H, Leinonen E. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol 1994;4:145-50.
11. Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 1995;10:S125-33.
12. Montgomery S. Clinically relevant effect sizes in depression. Eur Neuropsychopharmacol 1994;4:283-4.
13. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991; 10:1665-77.
14. Høyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, et al. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand 1996;93:184-90.
15. Mullin J, Lodge A, Bennie E, McCreadie R, Bhatt GS, Fenton G. A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with depression. J Psychopharmacol 1996; 10:235-40.
16. Zivkov M, de Jongh GD. Org 3770 versus amitriptyline: a 6-week randomized double-blind trial in hospitalized depressed patients. Hum Psychopharmacol 1995;10:173-80.
17. Zivkov M, Roes KCB, Pols AG. Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: a meta-analysis. Hum Psychopharmacol 1995;10[suppl 2]:S135-45.
18. Richou H, Ruimy P, Charbaut J, Delisle JP, Brunner H, Patris M, et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum Psychopharmacol 1995;10:263-71.
19. Marttila M, Jääskelainen J, Järvi R, Romanov M, Miettinen E, Sorri P, et al. A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychopharmacol 1995;5:441-6.
20. Van Moffaert M, de Wilde J, Vereecken A, Dierick M, Evrard JL, Wilmotte J, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with depression. Int Clin Psychopharmacol 1995;10:3-9.
21. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 1986;90:131-8.
22. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-99.
23. Danish University Antidepressant Group. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1993;28:105-16.
24. Kasper S. The rationale for long-term antidepressant therapy. Int Clin Psychopharmacol 1993;8:225-35.
25. Bremner JD, Smith WT. Org 3770 vs amitriptyline in the continuation treatment of depression: a placebo controlled trial. Eur J Psychiatry 1996;10:5-15.
26. Bech P, Allerup P, Reisby N, Gram LF. Assessment of symptom change from improvement curves on the Hamilton depression scale in trials with antidepressants. Psychopharmacology 1984;84:276-81.
27. Fox T. Drug treatment of anxiety and depression. Practitioner 1991;235:681-3.
28. Rudorfer MV, Manji HK, Potter WZ. Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 1994; 10:18-46.
29. Henry JA, Alexander CA, Sener EK. Relative mortality from over-dose of antidepressants. BMJ 1995;310:221-4.
30. De Jonghe F, Swinkels JA. The safety of antidepressants. Drugs 1992;43[suppl 2]:40-7.
31. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992;53:61-6.
32. Doogan DP. Toleration and safety of sertraline: experience worldwide. Int Clin Psychopharmacol 1991;6[suppl 2]:47-56.
33. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148:705-13.
34. Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993;54:289-99.
35. Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8:238-49.
36. Physicians' Desk Reference®. Montvale, NJ: Medical Economics Data Production Company, 1996.